Recursion Pharmaceuticals Inc vs SpaceX — how do they compare? Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B), while SpaceX trades at $166.89 (market cap $2.18T). The key difference: SpaceX is far larger — about 1018.7× Recursion Pharmaceuticals Inc's market cap, and SpaceX is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and SpaceX for 41 Days on average.
| RXRX | SPCX | |
|---|---|---|
Market Cap | $2.14B | $2.18T |
Volume | 30,789,535 | 68,508,567 |
Sector | Health | Industrials |
52-Week High | $6.79 | $202.09 |
52-Week Low | $2.84 | $108.27 |
Typical Hold Time | 22 Days | 41 Days |
Enterprise Value | $1.66B | $2.12T |
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →